Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | ATM | Q13315 | 2/20 | 0.55 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ESR1 | P03372 | 2/20 | 0.47 |
| ▸ | SHBG | P04278 | 1/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.47 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1734687 | 0.93 | NPC1 (0.52) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL1733618 | 0.87 | NPC1 (0.47) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL1734591 | 0.86 | NPC1 (0.46) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL1734187 | 0.85 | CYP19A1 (0.57) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL4656453 | 0.81 | MEN1 (0.76) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL31511903 | 0.81 | MEN1 (0.76) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL1840837 | 0.78 | MEN1 (0.67) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL31511909 | 0.78 | MEN1 (0.67) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL2292369 | 0.78 | CYP19A1 (0.71) | MEN1KMT2AALDH1A1HPGDNPC1 | |
| SCHEMBL30129997 | 0.78 | CYP19A1 (0.71) | MEN1KMT2AALDH1A1HPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8715761-B2 | Flavor molecules | GIVAUDAN S.A. (CH) | 2014-05-06 | — | — | US | disclosed |
| US-8715761-B2 | Flavor molecules | GIVAUDAN S.A. (CH) | 2014-05-06 | — | — | US | disclosed |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-10-24 | — | — | US | disclosed |
| US-8449936-B2 | Flavor molecules | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| US-8449936-B2 | Flavor molecules | GIVAUDAN SA (CH) | 2013-05-28 | — | — | US | disclosed |
| WO-2012054528-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100272656-A1 | Flavor Molecules | GIVAUDAN SA (CH) | 2010-10-28 | — | — | US | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
| US-20100040753-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2010-02-18 | — | — | US | disclosed |
| WO-2009105906-A1 | FLAVOR MOLECULES | GIVAUDAN SA (CH) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272656-A1 | Flavor Molecules | TAS2R30, TAS2R31, TAS2R1 | MEN1 952/4885KMT2A 1632/4885ALDH1A1 683/4885 |
| US-20100040753-A1 | FLAVOR MOLECULES | TAS2R30, TAS2R31, TAS2R1 | MEN1 952/4885KMT2A 1632/4885ALDH1A1 683/4885 |
| US-20130281387-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | MEN1 3628/4885KMT2A 3838/4885ALDH1A1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.